KROS earnings date and last-quarter result: last quarter miss, P/E -4.18. Updated 2026-07-23.
Keros Therapeutics (KROS) Research Hub
Keros Therapeutics (KROS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 11.33 USD (+0.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.18, market cap 0.33B. This hub links to the full technical, earnings and options research available for KROS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.33 USD (+0.44%) |
| 52-week range | 9.69 USD – 12.26 USD |
| Trend regime | Range |
| 14-day RSI | 54.5 (Neutral) |
| Trailing P/E | -4.18 |
| Market cap | 0.33B |
| Dividend yield | 0.00% |
Available research for KROS
Covered Call on KROS: how it works, illustrative setup around the real 11.33 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KROS: how it works, illustrative setup around the real 11.33 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KROS: how it works, illustrative setup around the real 11.33 USD price, max profit/loss, breakeven and when to use it. Educational.
KROS technical analysis: range, last 11.33 USD, RSI 54.5, 52w range 9.69 USD–12.26 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KROS in?
Keros Therapeutics (KROS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KROS in an uptrend or downtrend?
As of 2026-10-26, KROS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KROS's trailing P/E ratio?
KROS's trailing P/E is -4.18, with a market cap of 0.33B. See the earnings research page for full valuation detail.